Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Iron maldistribution has been implicated in multiple diseases, including the anemia of inflammation (AI), atherosclerosis, diabetes, and neurodegenerative disorders. Iron metabolism is controlled by hepcidin, a 25-amino acid peptide. Hepcidin is induced by inflammation, causes iron to be sequestered, and thus, potentially contributes to AI. Human hepcidin (hHepc) overexpression in mice caused an iron-deficient phenotype, including stunted growth, hair loss, and iron-deficient erythropoiesis. It also caused resistance to supraphysiologic levels of erythropoiesis-stimulating agent, supporting the hypothesis that hepcidin may influence response to treatment in AI. To explore the role of hepcidin in inflammatory anemia, a mouse AI model was developed with heat-killed Brucella abortus treatment. Suppression of hepcidin mRNA was a successful anemia treatment in this model. High-affinity antibodies specific for hHepc were generated, and hHepc knock-in mice were produced to enable antibody testing. Antibody treatment neutralized hHepc in vitro and in vivo and facilitated anemia treatment in hHepc knock-in mice with AI. These data indicate that antihepcidin antibodies may be an effective treatment for patients with inflammatory anemia. The ability to manipulate iron metabolism in vivo may also allow investigation of the role of iron in a number of other pathologic conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neutralizing hepcidin antibodies were shown to modulate iron metabolism in mice and cynomolgus monkeys; moreover, they improved erythropoiesis and responses to ESA therapy in mouse models of ACD (Sasu et al., 2010; Cooke et al., 2013).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Sasu et al., 2010
In the citing paper
“Neutralizing hepcidin antibodies were shown to modulate iron metabolism in mice and cynomolgus monkeys; moreover, they improved erythropoiesis and responses to ESA therapy in mouse models of ACD (Sasu et al., 2010; Cooke et al., 2013).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Sasu et al., 2010
In the citing paper
“Thus, elevated hepcidin concentrations during inflammation and infections contribute to hypoferremia [11,21] and, if chronic, to iron-restricted erythropoiesis and anemia [22].”
From Rapidly Escalating Hepcidin and Associated Serum Iron Starvation Are Features of the Acute Response to Typhoid Infection in Humans (2015) · cites this paper as [22]
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T., & Wanner, C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00273.x · Cited by 1,531
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417
Nicolas, G., Bennoun, M., Devaux, I., Beaumont, C., Grandchamp, B., Kahn, A., & Vaulont, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151179498 · Cited by 1,233
C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients
Yeun, J. Y., Levine, R. A., Mantadilok, V., & Kaysen, G. A. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70200-9 · Cited by 887
Severe iron deficiency anemia in transgenic mice expressing liver hepcidin
Nicolas, G., Bennoun, M., Porteu, A., Mativet, S., Beaumont, C., Grandchamp, B., Sirito, M., Sawadogo, M., Kahn, A., & Vaulont, S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072632499 · Cited by 880
Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis
Roetto, A., Papanikolaou, G., Politou, M., Alberti, F., Girelli, D., Christakis, J., Loukopoulos, D., & Camaschella, C. (2003) · Nature Genetics · doi:10.1038/ng1053 · Cited by 860
Weinstein, D. A., Roy, C. N., Fleming, M. D., Loda, M. F., Wolfsdorf, J. I., & Andrews, N. C. (2002) · Blood · doi:10.1182/blood-2002-04-1260 · Cited by 632
Intracellular iron transport and storage: from molecular mechanisms to health implications
Mackenzie, E. L., Iwasaki, K., & Tsuji, Y. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1893 · Cited by 526
Cited by
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Two to tango: Regulation of Mammalian iron metabolism
Hentze, M. W., Muckenthaler, M. U., Galy, B., & Camaschella, C. (2010) · Cell · doi:10.1016/j.cell.2010.06.028 · Cited by 2,120
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Weiss, G., Ganz, T., & Goodnough, L. T. (2019) · Blood · doi:10.1182/blood-2018-06-856500 · Cited by 1,219
Ganz, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2013 · Cited by 1,122
“In the hope that new approaches would increase the safety and efficacy of the treatment of these anemias, hepcidin antagonists have been developed targeting either hepcidin itself or its regulators (TABLE 3) and show substantial promise in preclinical animal models of anemia of inflammation and anemia of renal failure…”
Background
Metadata
- Authors
- Sasu, B. J., Cooke, K. S., Arvedson, T. L., Plewa, C., Ellison, A. R., Sheng, J., Winters, A., Juan, T., Li, H., Begley, C. G., & Molineux, G.
- Affiliations
- Departments of Hematology/Oncology,
- Protein Sciences, and
- Amgen (United States) (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-04-29
- Volume
- 115
- Issue
- 17
- Pages
- 3616-3624
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1987460376
- Cited by
- 251
- References
- 42
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 7 · 2023: 8 · 2022: 5 · 2021: 13 · 2020: 22 · 2019: 11 · 2018: 9 · 2017: 18 · 2016: 23 · 2015: 13 · 2014: 20 · 2013: 32 · 2012: 21
- FWCI
- 18.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- hepcidin, iron metabolism, anemia of chronic disease, Brucella abortus, erythropoiesis, iron sequestration, antibody neutralization, knock-in mice, mouse model
- MeSH terms
- Animals, Brucella abortus, Disease Models, Animal, Erythropoiesis, Humans, Inflammation, Iron, Mice, Transgenic, Anemia, Iron-Deficiency, Antimicrobial Cationic Peptides, Mice, Antibodies, Neutralizing, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. https://app.cochat.ai/papers/10.1182/blood-2009-09-245977
- The paper
- Sasu, B. J., Cooke, K. S., Arvedson, T. L., Plewa, C., Ellison, A. R., Sheng, J., Winters, A., Juan, T., Li, H., Begley, C. G., & Molineux, G. (2010). Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. https://doi.org/10.1182/blood-2009-09-245977
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.